Recombinant Human PLDN Protein，His

PLDN (Pegylated L-asparaginase) is a recombinant enzyme that plays a vital role in the treatment of acute lymphoblastic leukemia (ALL) and other malignancies by targeting and depleting asparagine, an amino acid critical for the growth of asparagine-dependent tumor cells. Traditional forms of L-asparaginase derived from microbial sources are associated with significant immunogenicity and a short half-life, leading to potential therapeutic challenges. To address these limitations, research has focused on the development of PLDN, which is engineered to improve its pharmacokinetic properties through pegylation—an innovative process that involves attaching polyethylene glycol (PEG) chains to the protein. This modification not only enhances the stability and solubility of L-asparaginase but also reduces its immunogenicity and prolongs its circulation time in the bloodstream, thereby allowing for more effective and sustained therapeutic effects. Clinical studies have begun to demonstrate that PLDN can improve patient outcomes with reduced side effects compared to traditional L-asparaginase formulations. Consequently, ongoing research aims to optimize PLDN's formulation and administration protocols while investigating its efficacy in diverse patient populations. The continued exploration of PLDN and other recombinant proteins underscores the importance of biopharmaceutical advancements in providing targeted and individualized cancer therapies.